The strong beat and guidance raise confirm accelerating momentum in core businesses. The lowered free cash flow guidance is a minor offset, reflecting investment for growth. Traders should watch the upcoming earnings call for details on the Thermo Fisher supply agreement and OSA market entry timeline.
Price Chart
Executive Summary
LivaNova reported Q2 2026 revenue of $390.6M (+10.8% YoY) and adjusted diluted EPS of $1.26, beating consensus estimates of $1.09 by 15.6%. The company raised full-year 2026 revenue growth guidance to 8%-9% (from 7%-8%) and adjusted EPS guidance to $4.30-$4.40 (from $4.20-$4.30), reflecting strong execution in Cardiopulmonary and Neuromodulation. A favorable Italian tax ruling generated a $95.4M discrete benefit, boosting GAAP EPS to $1.93, but the core beat and guidance raise are the primary drivers for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $390.6M (+10.8% reported, +9.8% constant-currency) beat consensus of $380.6M.
- Adjusted diluted EPS of $1.26 beat consensus of $1.09 by 15.6%.
- Full-year 2026 revenue growth guidance raised to 8%-9% constant-currency (from 7%-8%).
- Full-year 2026 adjusted EPS guidance raised to $4.30-$4.40 (from $4.20-$4.30).
- Cardiopulmonary revenue grew 11.2% reported; Neuromodulation grew 10.1% reported.
- Received a favorable Italian tax ruling, recognizing a $95.4M discrete tax benefit.
- Adjusted free cash flow guidance lowered to $140M-$160M (from $160M-$180M) due to strategic investments.
Financial Impact
Revenue beat of ~$10M vs consensus; EPS beat of $0.17 vs consensus; guidance raise adds ~$0.10 to midpoint of full-year EPS.
Risk Factors
- Lowered adjusted free cash flow guidance ($140M-$160M vs prior $160M-$180M) signals higher capex.
- Foreign exchange headwinds and supply chain risks remain.
- Execution risk on OSA market entry and Cardiopulmonary capacity expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001639691-26-000085 |
| Document: livn-20260805.htm | 0001639691-26-000085 |
| Document: 0001639691-26-000085-index-headers.html | 0001639691-26-000085 |
| Document: 0001639691-26-000085-index.html | 0001639691-26-000085 |
| Document: 0001639691-26-000085.txt | 0001639691-26-000085 |
| 8-K Data (Synthetic) | 0001639691-26-000085 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Insider Cluster | $79.47 $78.49 | ▼ −1.23% | ▼ −3.34% | $75.07 (−5.54%) |
Aug 5, 2026 8w ago | 8-K | $78.15 $80.78 | ▲ +3.37% | ▲ +3.02% | $75.07 (−3.93%) |
May 6, 2026 21w ago | 8-K | $66.26 $71.75 | ▲ +8.29% | ▲ +7.15% | $75.07 (+13.30%) |
Apr 29, 2026 22w ago | DEFA14A | $58.92 $66.26 | ▲ +12.46% | ▲ +9.35% | $75.07 (+27.41%) |
Feb 25, 2026 31w ago | 8-K | $70.29 $65.26 | ▼ −7.16% | ▼ −6.06% | $75.07 (+6.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access